RxDoctor Payments Data

Mario Espinosa Garcia, MD

Pulmonary Disease · Bayamon, PRNPI 1083653141

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,980 of the $5,105 with a category attached, or 78.0%. 14 manufacturers reported payments, led by GSK at 32.3% of the total. Reporting peaked in 2024 at $1,650 and has fallen 59.7% since, to $665 in 2025.

$5,105in general payments, 2019–2025

Across 118 payments — averaging $43.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Merck$1K
  • Boehringer Ingelheim$322
  • Genentech USA, Inc.$67
  • Mylan Specialty L.p.$64
  • plus $306 from 8 others

What the payments were for

  • Speaking & faculty fees$1,12522%
  • Food & beverage$3,98078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK52$1,647
AstraZeneca38$1,534
Merck2$1,164
Boehringer Ingelheim10$322
Genentech USA, Inc.1$67
Mylan Specialty L.p.3$64
Amgen3$63
Jazz Pharmaceuticals Inc.1$63
Mylan LLC3$43
United Therapeutics Corporation1$35
Harmony Biosciences LLC1$33
PBG Puerto Rico LLC1$25
Viatris Specialty LLC1$24
Pfizer Pharmaceuticals LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,105 in reported general payments places this provider in the 70th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,108
Medicare patients
29
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate61$800,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter280$188,915
Breo ElliptaFluticasone/Vilanterol302$126,608
FasenraBenralizumab15$86,033
Spiriva RespimatTiotropium Bromide103$55,162
Stiolto RespimatTiotropium Br/Olodaterol Hcl92$44,951
NucalaMepolizumab11$39,766
Spiriva HandihalerTiotropium Bromide68$35,808
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate162$34,717
SymbicortBudesonide/Formoterol Fumarate126$28,424
Wixela InhubFluticasone Propion/Salmeterol180$24,032
Atrovent HfaIpratropium Bromide47$22,254
Albuterol Sulfate HfaAlbuterol Sulfate506$20,077
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,821
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$322$908,900272 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$1,647$366,346616 claims
AstraZenecaFasenra, Symbicort, Breztri Aerosphere$1,534$126,279159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →